Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Clin Infect Dis. 2013 Aug;57(4):513-20. doi: 10.1093/cid/cit320. Epub 2013 May 10.
Azole resistance is an emerging problem in Aspergillus fumigatus and complicates the management of patients with Aspergillus-related diseases. Selection of azole resistance may occur through exposure to azole fungicides in the environment. In the Netherlands a surveillance network was used to investigate the epidemiology of resistance selection in A. fumigatus.
Clinical A. fumigatus isolates were screened for azole resistance in 8 university hospitals using azole agar dilution plates. Patient information was collected using an online questionnaire and azole-resistant A. fumigatus isolates were analyzed using gene sequencing, susceptibility testing, and genotyping. Air sampling was performed to investigate the presence of resistant isolates in hospitals and domiciles.
Between December 2009 and January 2011, 1315 A. fumigatus isolates from 921 patients were screened. A new cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) was observed in 21 azole-resistant isolates from 15 patients in 6 hospitals. TR46/Y121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration ≥16 mg/L). Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment failed in all 5 patients receiving primary therapy with voriconazole. TR46/Y121F/T289A Aspergillus fumigatus was recovered from 6 of 10 sampled environmental sites.
We describe the emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive aspergillosis. Recovery of TR46/Y121F/T289A from the environment suggests an environmental route of resistance selection. Exposure of A. fumigatus to azole fungicides may facilitate the emergence of new resistance mechanisms over time, thereby compromising the use of azoles in the management of Aspergillus-related diseases.
唑类耐药性是烟曲霉中出现的一个问题,使曲霉相关疾病患者的管理变得复杂。唑类耐药性的选择可能是通过接触环境中的唑类杀真菌剂而发生的。在荷兰,使用监测网络调查了烟曲霉中耐药性选择的流行病学。
在 8 所大学医院使用唑类琼脂稀释板对临床烟曲霉分离株进行唑类耐药性筛选。通过在线问卷收集患者信息,并使用基因测序、药敏试验和基因分型分析唑类耐药烟曲霉分离株。进行空气采样以调查医院和家庭中耐药分离株的存在。
在 2009 年 12 月至 2011 年 1 月期间,对来自 921 名患者的 1315 株烟曲霉分离株进行了筛选。在来自 6 家医院的 15 名患者的 21 株唑类耐药分离株中观察到一种新的 Cyp51A 介导的耐药机制(TR46/Y121F/T289A)。TR46/Y121F/T289A 分离株对伏立康唑高度耐药(最小抑菌浓度≥16mg/L)。8 例患者因 TR46/Y121F/T289A 而患有侵袭性曲霉病,所有 5 例接受伏立康唑初始治疗的患者均治疗失败。从 10 个采样环境点中的 6 个回收了 TR46/Y121F/T289A 烟曲霉。
我们描述了一种伏立康唑高度耐药的烟曲霉的出现和地理迁移,该耐药性与侵袭性曲霉病患者伏立康唑治疗失败有关。从环境中回收 TR46/Y121F/T289A 表明存在耐药性选择的环境途径。随着时间的推移,烟曲霉暴露于唑类杀真菌剂可能会促进新耐药机制的出现,从而影响唑类药物在曲霉相关疾病管理中的应用。